EricMichaelLanderMD(He/Him)
Oncology • Minneapolis, MNHematologic Oncology
Clinical Fellow Hematology/Oncology - Vanderbilt University Medical Center
Dr. Lander is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
910 E 26th St
Ste 200
Minneapolis, MN 55404Phone+1 612-884-6300Fax+1 612-884-6363
Summary
- Dr. Eric Lander is an oncologist in Nashville, TN and is affiliated with multiple hospitals in the area, including Nashville General Hospital, Tennessee Valley Healthcare System, and Tennessee Valley Healthcare System. He received his medical degree from University of Arizona College of Medicine-Tucson and has been in practice 4 years. He specializes in hematologic oncology. He has numerous publications in peer-reviewed journals and experience in clinical trial design.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2021 - 2024- Vanderbilt University Medical CenterResidency, Internal Medicine, 2018 - 2021
University of Arizona College of MedicineClass of 2018
Certifications & Licensure
TN State Medical License 2022 - 2026
MN State Medical License 2024 - 2025- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 3 citationsGastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.Matthew R Strickland, Eric M Lander, Michael K Gibson, David H Ilson, Jaffer A Ajani
Journal of the National Comprehensive Cancer Network. 2024-03-19 - 10 citationsEsophageal Cancer: Overview, Risk Factors, and Reasons for the Rise.Steve Lander, Eric Lander, Michael K Gibson
Current Gastroenterology Reports. 2023-11-01 - 3 citationsUsing the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer.Eric M Lander, Katherine C Rappazzo, Li-Ching Huang, Jiun-Ruey Hu, Heidi Chen
The Oncologist. 2023-02-08
Press Mentions
Natera Announces New Signatera™ MRD Data at 2023 AACR Annual MeetingApril 14th, 2023- New Signatera™ MRD Data in Gastrointestinal Cancers to Be Presented at the ASCO GI Symposium 2023January 19th, 2023
- New Signateratm MRD Data in Gastrointestinal Cancers to Be Presented at the ASCO GI Symposium 2023January 19th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
